Addictive Potential: Medium
Emergency Room Visits Yearly: Unknown
Mandatory Minimum Sentence: Unknown
Mechanism of Action: μ opioid receptor agonist
MT-45 is also known as IC-6 and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine. MT-45 was first created in the 1970′s by a Japanese pharmaceutical company. Still, it wasn’t found in recreational drug distribution until 2013. Since it is an N,N-disubstituted piperazine, it is structurally unrelated to most other opioid drugs. Nevertheless, the analgesic activity of MT-45 was found to be comparable to morphine in animal studies (EMCDDA, 2014).
As explained by the EMCDDA (2014), recreational users have reported using a range of doses and routes of administration: “oral doses were between 25–75 mg with re-dosing reported; doses for nasal insufflation were between 15–20 mg (this route of administration was noted by several users to cause an intolerable level of irritation); one user reported rectal administration of ’80 mg of MT-45 salt as the solution’; the same user also reported smoking 30–50 mg of MT-45 base, which he prepared from the dihydrochloride salt.”
Side Effects and Adverse Reactions:
There is currently limited empirical data available on the side effects, adverse reactions, long term damage, and/or addiction potential of MT-45. According to the EMCDDA (2014) and Helander et al. (2014) some of the potential negative effects include:
- respiratory depression
- persisting bilateral hearing loss after use
- potentially addictive and may cause withdrawal symptoms
Remember, research chemicals are experimental chemicals that are not approved for human consumption. This is because not enough data exists currently about their effects in humans. Although some people are willing to ingest MT-45, it is unreasonable to assume that it is in any way safe to use recreationally.
Deaths and Overdoses:
In August of 2013, two users died of acute intoxication with MT-45 in the United States. And as of April 2014, Swedish officials reported 21 deaths associated with MT-45 (EMCDDA, 2014).
- Comparative study of 1-cyclohexyl-4-(1, 2-diphenylethyl)-piperazine and its enantiomorphs on analgesic and othe pharmacological activities in experimental animals
- 1-Substituted 4-(1, 2-diphenylethyl) piperazine derivatives and their analgesic activities
- 1-Substituted-4-(1, 2-diphenylethyl) piperazine derivatives and compositions containing the same
- Synthesis and structure-activity relationships of 1-substituted 4-(1, 2-diphenylethyl) piperazine derivatives having narcotic agonist and antagonist activity
- Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111)
- MT-45, a new psychoactive substance associated with hearing loss and unconsciousness